3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
78
Prostatic Neoplasms
56
Breast Neoplasms
50
Lung Neoplasms
31
Neoplasms
20
Neoplasm Metastasis
18
Stomach Neoplasms
14
Head and Neck Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Recurrence
7
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Adenocarcinoma of Lung
7
Sarcoma
6
Esophageal Neoplasms
6
Carcinoma, Transitional Cell
5
Carcinoma, Squamous Cell
5
Urinary Bladder Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Triple Negative Breast Neoplasms
3
Advanced Non-Small Cell Lung Cancer
3
Adenocarcinoma, Bronchiolo-Alveolar
3
Solid Tumor
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Inflammatory Breast Neoplasms
2
Hormone Refractory Prostate Cancer
2
HER2-positive Breast Cancer
2
Fallopian Tube Neoplasms
2
Interventions
vofatamab
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
pembrolizumab
1
palbociclib
1
atezolizumab
1
Sunitinib
1
Standard of Care
1
Mitomycin
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urologic Diseases
×
Docetaxel
×
Clear all
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts